Ionis Pharmaceuticals, Inc. (IONS)
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
IONS reports better-than-expected top and bottom-line numbers for the fourth quarter.
Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q4 2024 Earnings Conference Call February 19, 2025 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Kyle Jenne - Chief Global Product Strategy Officer Richard Geary - Chief Development Officer Elizabeth Hougen - Chief Financial Officer Eugene Schneider - Chief Clinical Development and Operations Officer Conference Call Participants Michael Ulz - Morgan Stanley Jessica Fye - JPMorgan Chase & Co. Akash Tewari - Jefferies Yanan Zhu - Wells Fargo Securities Jay Olson - Oppenheimer & Co. Chi Fong - Bank of America Merrill Lynch Gary Nachman - Raymond James & Associates, Inc. Yaron Werber - TD Cowen Operator Good morning, and welcome to Ionis' Fourth Quarter and Full-Year 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval
Ionis Pharmaceuticals' Q4 earnings beat expectations, but guidance for 2025 was slightly below consensus, leading to a HOLD rating pending further catalysts. TRYNGOLZA's approval for FCS is promising, but expansion into the larger sHTG market by 2025 is crucial for the company to reach profitability and satisfy analyst's estimates. Ionis has a strong cash position and a robust pipeline of over 40 RNA-targeted therapeutics, making it a compelling watch-list candidate.
Ionis Pharma Beats Expectations for Q4
Ionis Pharmaceuticals (IONS 0.44%), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis outperformed analysts' top-line expectations with revenue of $227 million compared to the anticipated $135 million.
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales
On Wednesday, Ionis Pharmaceuticals Inc IONS reported a fourth-quarter EPS loss of $0.66, up from a loss of $0.06, beating the consensus of a $1.10 loss.
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $0.06 per share a year ago.
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned drug to receive marketing approval.
US FDA approves Ionis Pharma's genetic disorder drug
The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's website showed on Thursday.
